MTT5
MTT5, a TLR7 agonist, is conjugated to Deruxtecan to create a bifunctional agent for HER2-positive solid tumors. This conjugate combines targeted tumor cell killing with immune system activation via TLR7 stimulation, supporting research in antibody-drug conjugates and immuno-oncology for both in vitro and in vivo studies.
Product Specifications
Field of Research
Immunology & Inflammation
Molecular Formula
C22H27N7O4
Molecular Weight
453.49
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K1119603 1.0 µg DNA
KCNH4 sgRNA CRISPR Lentivector (Human) (Target 2)
Sign In for Pricing
View Details 
TF0112-01 1 mg
1,2-Dipalmitoyl-sn-glycero-3-phosphoserine sodium salt
Sign In for Pricing
View Details